16 November 2021
The creation of the domestic therapy that allows to interrupt the development of coronavirus at the initial stage is at the final stage. This is reported by TASS with reference to Mikhail Murashko, the Minister of Health of the Russian Federation.
“So far, unfortunately, no one has it [a cure for covid], although we are close to the completion of a drug that stops the course of the disease at the initial stage of infection,” the minister is quoted as saying.
Murashko said that he would specify what drug he was talking about after his tests have been completed. As he also noted, all medicines for coronavirus infection are now available in Russia.
“There is probably only one foreign medicine the supply of which became limited, because manufacturers physically do not have time to produce enough for the whole world. We have created an alternative drug. It is necessary to have a domestic product line,” the head of the Ministry of Health of the Russian Federation said in an interview with the publication.
Aleksander Ginzburg, the head of the Gamaleya Center, recently spoke about the development of a drug that suppresses the reproduction of coronavirus. Moreover, the Gamaleya Center is developing an antibody-based drug to treat COVID-19 patients. Clinical trials of the drug should start in January 2022 and be completed within three to four months. Earlier it also became known that scientists of the Russian Ministry of Defense have created a dietary supplement against coronavirus.
Print06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
From January to August 2024, Russia’s medicinal product production totaled 530.7 billion rubles
27 September 2024
The government has expanded medicine sales in villages without pharmacies
27 September 2024
FDA issues draft guidance to help industry conduct global cancer clinical trials
26 September 2024
Optimizing Patient Support Through Effective Information Governance: Balancing Risks and Rewards
26 September 2024